177 related articles for article (PubMed ID: 22441566)
1. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Wong NS; Fernando NH; Nixon AB; Cushman S; Aklilu M; Bendell JC; Morse MA; Blobe GC; Ashton J; Pang H; Hurwitz HI
Anticancer Res; 2011 Jan; 31(1):255-61. PubMed ID: 21273607
[TBL] [Abstract][Full Text] [Related]
3. Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.
Bruera G; Cannita K; Giordano AV; Vicentini R; Ficorella C; Ricevuto E
Int J Oncol; 2014 Jan; 44(1):17-26. PubMed ID: 24247407
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF
Kang S; Lee MW; Song IC; Lee HJ; Yun HJ; Jo DY; Kim JS; Kwon JH; Kim JY; Lee KH; Ryu H
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7819-7829. PubMed ID: 37031435
[TBL] [Abstract][Full Text] [Related]
5. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
Liu Y; Starr MD; Bulusu A; Pang H; Wong NS; Honeycutt W; Amara A; Hurwitz HI; Nixon AB
Cancer Med; 2013 Apr; 2(2):234-42. PubMed ID: 23634291
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
Feliu J; Safont MJ; Salud A; Losa F; García-Girón C; Bosch C; Escudero P; López R; Madroñal C; Bolaños M; Gil M; Llombart A; Castro-Carpeño J; González-Barón M
Br J Cancer; 2010 May; 102(10):1468-73. PubMed ID: 20424611
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
García-Alfonso P; Muñoz-Martin AJ; Alvarez-Suarez S; Jerez-Gilarranz Y; Riesco-Martinez M; Khosravi P; Martin M
Br J Cancer; 2010 Nov; 103(10):1524-8. PubMed ID: 20978503
[TBL] [Abstract][Full Text] [Related]
8. Expanded RAS: refining the patient population.
Atreya CE; Corcoran RB; Kopetz S
J Clin Oncol; 2015 Mar; 33(7):682-5. PubMed ID: 25584005
[No Abstract] [Full Text] [Related]
9. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.
Macedo LT; da Costa Lima AB; Sasse AD
BMC Cancer; 2012 Mar; 12():89. PubMed ID: 22414244
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients.
Sun DC; Shi Y; Wang YR; Lv Y; Yan H; Mao H; Wang ZK; Wu ZY; Shi WW; Dai GH
Sci Rep; 2017 Oct; 7(1):14368. PubMed ID: 29085005
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
da Silva WC; de Araujo VE; Lima EMEA; Dos Santos JBR; Silva MRRD; Almeida PHRF; de Assis Acurcio F; Godman B; Kurdi A; Cherchiglia ML; Andrade EIG
BioDrugs; 2018 Dec; 32(6):585-606. PubMed ID: 30499082
[TBL] [Abstract][Full Text] [Related]
12. Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
Díaz-Rubio E; Pietrantonio F; de Braud F
Oncologist; 2012; 17(11):1426-8. PubMed ID: 23073991
[TBL] [Abstract][Full Text] [Related]
13. Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.
Pinto C; Di Fabio F; Rosati G; Lolli IR; Ruggeri EM; Ciuffreda L; Ferrari D; Lo Re G; Rosti G; Tralongo P; Ferrara R; Alabiso O; Chiara S; Ianniello GP; Frassoldati A; Bilancia D; Campanella GA; Signorelli C; Racca P; Benincasa E; Stroppolo ME; Di Costanzo F
Cancer Med; 2016 Nov; 5(11):3272-3281. PubMed ID: 27748041
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.
Abajo A; Rodriguez J; Bitarte N; Zarate R; Boni V; Ponz M; Chopitea A; Bandres E; Garcia-Foncillas J
Br J Cancer; 2010 Nov; 103(10):1529-35. PubMed ID: 20940716
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.
Altomare I; Bendell JC; Bullock KE; Uronis HE; Morse MA; Hsu SD; Zafar SY; Blobe GC; Pang H; Honeycutt W; Sutton L; Hurwitz HI
Oncologist; 2011; 16(8):1131-7. PubMed ID: 21795432
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer.
Kavgaci G; Dizdar O; Yalcin S
Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutant colorectal tumors: past and present.
Brand TM; Wheeler DL
Small GTPases; 2012; 3(1):34-9. PubMed ID: 22714415
[TBL] [Abstract][Full Text] [Related]
18. Unsupported off-label chemotherapy in metastatic colon cancer.
de Souza JA; Polite B; Perkins M; Meropol NJ; Ratain MJ; Newcomer LN; Alexander GC
BMC Health Serv Res; 2012 Dec; 12():481. PubMed ID: 23272659
[TBL] [Abstract][Full Text] [Related]
19. Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.
McFall T; Schomburg NK; Rossman KL; Stites EC
Cell Commun Signal; 2020 Nov; 18(1):179. PubMed ID: 33153459
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
Arai H; Yang Y; Baca Y; Millstein J; Denda T; Ou FS; Innocenti F; Takeda H; Kubota Y; Doi A; Horie Y; Umemoto K; Izawa N; Wang J; Battaglin F; Jayachandran P; Algaze S; Soni S; Zhang W; Goldberg RM; Hall MJ; Scott AJ; Hwang JJ; Lou E; Weinberg BA; Marshall J; Goel S; Xiu J; Michael Korn W; Venook AP; Sunakawa Y; Lenz HJ
Eur J Cancer; 2024 Apr; 201():113914. PubMed ID: 38359495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
